BioCentury | Dec 9, 2020
Emerging Company Profile

Tallac: linking antibodies to DNA-triggered innate immunity

Tallac debuted last week with a $62 million series A round to advance a pipeline of systemically delivered antibody conjugates designed to trigger innate immunity against cancer.  The tranched round...
BioCentury | Oct 3, 2020
Translation in Brief

A SARS-CoV-2 genome degrader; neutralizing influenza B mAbs; Fulcrum’s sickle cell therapy increases fetal hemoglobin and more

Matt Disney’s small molecule RNA degraders for COVID-19A Scripps Research team led by Expansion Therapeutics Inc. founder Matthew Disney published an ACS Central Science study describing a small molecule that binds a SARS-CoV-2 hairpin RNA structure that...
BioCentury | Aug 28, 2020

Turning to solid tumors, cell therapy play Triumvira earns syndicate’s $55M vote of confidence

Since its 2015 launch, Triumvira has changed CEOs once, developed a third iteration of its engineered T cell therapeutics platform, and deprioritized a former lead program for blood cancer after it reached the IND stage. Now, the...
BioCentury | Jul 6, 2020
Product Development

July 6 Quick Takes: Cellectis CAR T trial halted; plus data readouts from Bellus, ObsEva, Idorsia, and more

Patient death prompts Cellectis trial halt FDA placed a clinical hold on an allogeneic CAR T therapy trial to treat multiple myeloma from Cellectis S.A. (NASDAQ:CLLS; Euronext:ALCLS) after a patient who received the second-level dose...
BioCentury | Jun 10, 2020
Emerging Company Profile

With $50M from Versant, Lycia takes targeted degradation outside the cell

Fourteen months after leading biochemist Carolyn Bertozzi published a preprint on a new class of compounds that degrade extracellular proteins inaccessible to PROTACs, Versant-built Lycia has emerged with $50 million to turn that technology into...
BioCentury | May 9, 2020
Product Development

With Nuevolution’s DNA-encoded libraries, Amgen takes on targeted degradation and beyond

Amgen’s 2019 takeout of DNA-encoded library (DEL) company Nuevolution is fueling the big biotech’s move into the crowded field of targeted protein degradation. The team that drove the acquisition will also use DELs to discover...
BioCentury | Mar 11, 2020

Arkin ramping up investments with $140M fund

Arkin Holdings closed its second biopharma fund Monday at $140 million, more than double its debut fund, which launched with $60 million in 2016 and was fully committed at the end of 2019. As with...
BioCentury | Feb 8, 2020
Tools & Techniques

Beyond PROTACs and the proteasome: broadening the TAC toolbox

The idea of sending disease-driving proteins to the cell’s garbage can is only the first act in a field that now centers around targeted degradation. In the sequel, researchers are extending the principle to other...
BioCentury | Jan 18, 2020
Product Development

Mapping the path to gene therapy 2.0

A series of incremental but important improvements on the existing gene therapies are starting to address some of the technology’s key limitations. But some argue it will take a major overhaul of manufacturing practices to...
BioCentury | Oct 11, 2019

Beyond diabetes: T1D Fund’s new remit broadens venture base

...SQZ’s $72 million series C round last year, and SQZ has started a preclinical program, TAC-T1D...
Items per page:
1 - 10 of 103